摘要 The diagnosis and treatment of benign prostatic obstruction (BPO) is based on a number of well-known lower urinary tract symptoms (LUTS) feared by all ageing males with functional testes. The ascent of modern urology turned this disease from lethal into an annoying but treatable health problem in the previous century. We are able to relieve the great majority of patients from their bothersome symptoms to a respectable quality of life by medication or removal of the obstructive part of the enlarged prostate. We can be proud of some progress made in the new millennium to reach a correct diagnosis and subsequent choice of treatment aiming for quality of life and cost-efficiency for public health. Still it remains symptomatic treatment and we expect the new generation of urologists to close some gaps in our knowledge on the regulation of prostatic growth to focus on prevention and elimination of the disease in the foreseeable future.
Abstract: The diagnosis and treatment of benign prostatic obstruction (BPO) is based on a number of well-known lower urinary tract symptoms (LUTS) feared by all ageing males with functional testes. The ascent of modern urology turned this disease from lethal into an annoying but treatable health problem in the previous century. We are able to relieve the great majority of patients from their bothersome symptoms to a respectable quality of life by medication or removal of the obstructive part of the enlarged prostate. We can be proud of some progress made in the new millennium to reach a correct diagnosis and subsequent choice of treatment aiming for quality of life and cost-efficiency for public health. Still it remains symptomatic treatment and we expect the new generation of urologists to close some gaps in our knowledge on the regulation of prostatic growth to focus on prevention and elimination of the disease in the foreseeable future.
通讯作者:
Louis Denis,E-mail address:louis.denis@skynet.be.
E-mail: louis.denis@skynet.be
引用本文:
Johan Braeckman, Louis Denis. Management of BPH then 2000 and now 2016-From BPH to BPO[J]. Asian Journal of Urology, 2017, 4(3): 138-147.
Johan Braeckman, Louis Denis. Management of BPH then 2000 and now 2016-From BPH to BPO. Asian Journal of Urology, 2017, 4(3): 138-147.
[1] Hinman Jr F, Boyarsky S, Caine M, Chisholm GD, Gammelgaard PA, Madsen PO, et al. Benign prostatic hypertrophy. New York:Springer-Verlag New York Inc; 1983. [2] Chatelain C, Denis L, Foo KT, Khoury S, McConnell J. Benign prostatic hyperplasia. UK:Plymbridge Distributors Ltd; 2001. [3] Foo KT. Diagnosis and treatment of benign prostate hyperplasia in Asia. Transl Androl Urol 2014;4:478-83. [4] Russo GI, Castelli T, Urzi D, Privitera S, La Vignera S, Condorelli RA, et al. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components:a systematic review. Int J Urol 2015;22:982-90. [5] Oelke M, Martinelli E. Pharmacological treatment of benign prostatic hyperplasia. Urol A 2016;55:81-94. [6] Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 2014;15:463. [7] Hu J, Zhang L, Zou L, Hu M, Fan J, Cai Y, et al. Role of inflammation in benign prostatic hyperplasia development among Han Chinese:a population-based and singleinstitutional analysis. Int J Urol 2015;22:1138-42. [8] Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS) incl. benign prostatic obstruction (BPO). European Assocaition of Urology; 2015. http://uroweb.org/guidelines/compilations-ofall-guidelines/. [9] Weiss J, Andersson F, Juul KV. Diagnosing nocturnal polyuria (NP)-based on self-reported nocturnal void volume and fluid intake in clinical practice:results from a real-world treatment survey in Europe and the USA. Munch, EAU16, abstract 536. [10] Heyns CF, van der Walt CL, Groeneveld AE. Correlation between a new visual prostate symptom score (VPSS) and uroflowmetry parameters in men with lower urinary tract symptoms. S Afr Med J 2012;102:237-40. [11] Foo KT. Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. Int J Urol 2010;17:974-9. [12] Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction. Sing Med J 2013;54:482-6. [13] Zheng J, Pan J, Qin Y, Huang J, Luo Y, Gao X, et al. Role for intravesical prostatic protrusion in lower urinary tract symptom:a fluid structural interaction analysis study. BMC Urol 2015;15:86. [14] Browne CT, Emberton M. Self-management for men with lower urinary tract symptoms. Curr Urol Rep 2009;10:261-6. [15] Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6. [16] Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol 2014;6:135-47. [17] Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal antiinflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia:systematic review and metaanalysis of randomized controlled trials. BJU Int 2013;111:304-11. [18] Roth SH. Understanding the COX-2/NSAID dilemma. Drugs 2005;65:1915-7. [19] Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebocontrolled phase 2 dose-ranging study of onabotulinumtoxin A in men with benign prostatic hyperplasia. Eur Urol 2013;63:496-503. [20] Delongchamps N, Descazeaud A, Benard A, Azzouzi R, Saussine C, De La Taille A, et al. A randomized clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox®) to optimized medical therapy in patients with BPHrelated LUTS:end-of-study results of the PROTOX trial. Eur Urol Suppl 2016;15. e1079-e1079a. [21] Michielsen DP, Coomans D, Braeckman JG, Umbrain V. Bipolar transurethral resection in saline:the solution to avoid hyponatraemia and transurethral resection syndrome. Scand J Urol Nephrol 2010;44:228-35. [22] Narayan P, Tewari A, Garzotto M, Parramore H, Schalow E, Starling E, et al. Transurethral vapotrode electrovaporization of the prostate:physical principles, technique, and results. Urology 1996;47:505-10. [23] Agrawal MS, Aron M, Goel R. Hemiresection of the prostate:short-term randomized comparison with standard transurethral resection. J Endourol 2005;19:868-72. [24] Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015;22:7772-82. [25] Elshal AM, Eldemerdash Y, Mekkawy R, Taha DE, Laymon M, ElNahas AR, et al. Prostate tissue retrieval after holmium laser enucleation of the prostate; assessment of non-morcellation approaches. Arab J Urol 2016;14:147-55. [26] Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2014;25:47-52. [27] Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation-image-guided robot-assisted waterjet ablation of the prostate:initial clinical experience. BJU Int 2016;117:923-9.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
